Osteodystrophy Fibrosa in a Juvenile Goat | Chapter 3 |Disease and Health: Research Developments Vol. 1

Osteodystrophy is a broad term used to encompass conditions where bones either fail to develop normally or experience abnormal metabolism despite being mature. Fibrous osteodystrophy is also called osteitis cystic fibrosa. Fibrous osteodystrophy is a metabolic disease in goats characterized by bone resorption due to prolonged hypersecretion of parathyroid hormone, often caused by diets high in phosphorus or low in calcium. In this case, an 8-month-old goat kid was brought to the Referral Veterinary Polyclinic of ICAR-IVRI with a history of anorexia and noticeable bilateral facial swelling. Upon further inquiry, it was found that the owner had been regularly feeding the kid a diet primarily consisting of wheat bran and barley. Clinical examination revealed the goat kid to be dull and depressed, though its rectal temperature remained within the normal range. Hematobiochemical analysis showed decreased serum calcium levels (7 mg/dl) and elevated maleate (AvilTM, 1 ml for 5 days), oral syrup CalcimustTM (5 ml for 5 days), intravenous injection of Calcium SandozTM (10 ml in 200 ml normal saline solution), and a single dose of anabolic steroid Nandrolone (50 mg). The owner was also advised to discontinue feeding wheat bran and barley immediately. It was concluded that timely diagnosis through hematobiochemical analysis and radiographic imaging, combined with appropriate therapeutic interventions including calcium supplementation, anabolic steroids, and dietary adjustments, resulted in a favourable outcome with complete recovery within 14 days. The kid began to show improvement after 5 days, with a full recovery observed 14 days post-treatment.

 

Author (s) Details

Ravi Dabas
Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, India.

 

Siraj Ansari
Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, India.

 

Pratyanshu Srivastava
Department of Veterinay Gynaecology and obstetrics, Duvasu, Mathura-281001, India.

 

Vinita Rajpurohit
Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, India.

 

Bhupender
Livestock Production and Management section, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, India.

 

Yogesh Soni
ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/dhrd/v1/3175

Evolving Therapeutic Approaches for Diabetes: Harnessing the Benefits of Herbal Remedies in the Modern Era | Chapter 3 | Current Overview on Pharmaceutical Science Vol. 6

 This division will discuss the use of herbaceous medicines as a situation approach for Diabetes Mellitus (DM), a disorder that is particularly prevailing in the Asian subcontinent. Specifically, this chapter will devote effort to something the treatment of Non-diabetes affecting the young (NIDDM) or Type 2 DM (T2DM). Herbal medicines have long happened the backbone of the curative system in India, and this chapter will survey the original, novel, and ancient habits of treating the disorder. Various plants accompanying anti-diabetic belongings, such as catechu, basil, Ginko biloba, fenugreek, etc, will be discussed painstakingly. Furthermore, several displayed herbal merchandise, such as Bitter fruit powder, episulin, Dia care, and much more, will be discussed. The member will explore the mechanisms of operation of these herbal merchandise and how they maybe effective cures for the disorder. The aim of this unit is to provide evidence that herbaceous products maybe effective situations for DM and to re-establish herbaceous drugs as a viable treatment approach.

Author(s) Details:

Sukanta Roy,
The Neotia University, Sarisha, West Bengal, India and TAAB Biostudy Services, Kolkata, West Bengal, India.

Shramana Majumder,
Covance India Pharmaceutical Services, Bengaluru, Karnataka, India.

Sourav Das,
The Neotia University, Sarisha, West Bengal, India and TAAB Biostudy Services, Kolkata, West Bengal, India.

Senjuti Bhattacharjee,
Child Fund India, 22, Museum Road, Bengaluru, Karnataka 560001, India.

Anirbandeep Bose,
TAAB Biostudy Services, Kolkata, West Bengal, India.

Subhasish Mondal,
The Neotia University, Sarisha, West Bengal, India.

Please see the link here: https://stm.bookpi.org/COPS-V6/article/view/9463

Empowering Molecular Network in the Pathogenesis of Obesity with Omics Architecture | Chapter 6 | Emerging Trends in Disease and Health Research Vol.4.

 Obesity is regarded as a major public health concern, owing to the multifaceted factors involved in metabolic complications rooted in multifactorial causes (e.g., environmental toxicity or genetic abnormality), as well as the unmet landscape of the health-care system in search of therapeutic or prevention methods. Evidence that supports Omics as a strategic tool of systemic biology is being used to define the wiring of the molecular circuit in metabolic malfunctions, as well as the evaluation of metabolic modulators such as synthetic drugs, stem cell replacement, and natural secondary metabolites derived from various sources. The link between the nutritional environment and cellular/genetic processes is referred to as nutritional genomics or Nutrigenomics. Its goal is to figure out how nutrition affects a person's genes and health. Nutrigenomics strives to give a genetic understanding of how common food ingredients (i.e., nutrition) modify the expression or structure of an individual's genetic makeup, hence affecting the balance of health and sickness. Furthermore, enhancing detection capabilities from patient clinical samples and monitoring illness progression in reserve populations, who may be at a higher risk of disease susceptibility due to numerous micro- and macro-environmental variables, remains a preventative thread in public health informatics. By utilising the omics platform, which includes epigenetics, metabolomics, nutrigenomics, transcriptomics, pharmacogenomics, and genomics, molecular-based detection systems can forecast evolving disease in terms of key molecule modifications that may contribute to disease pathogenesis and reflect heredity, such as quantitative trait loci, polymorphism, and epigenetic modification. Furthermore, a customised or personalised approach to treating metabolic disease could be applied by building a person's health algorithm in conjunction with a molecular chain-based surveillance and prevention system. To encourage effective biomarker discoveries in the field of molecular therapy and early detection target molecules in obesity, early diagnostic tools as a potential strategy has inspired us in clinical validation and assessment to improve prevention/treatment outcomes for a better translation medicine process. In this short review, we aim to better understand the interaction and connectivity between risks and metabolic disorders like obesity by utilising the molecular drive platform that OMICS technologies are worthy of developing a clinical assessment with regard to diagnosing, predicting, and treating metabolic disease chains (i.e., initiation, progress, and determination) and defining causative molecule-based wiring on host defence machinery after exposure to various unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown Nutrigenomics, as a crucial strategical method to detecting genetic variation or disclosing faults of the host defence system in metabolic disorders, can be used not only to assess one's risk for obesity, but also to treat obesity through the creation of individualised diet regimens.

Author(s) Details:

S. Bartley
Department of Public Health, Division of Environmental Health Science, New York Medical College, Valhalla NY 10595, USA.

H. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501, Jinju-City, Gyeongsangnamdo, 660-701, Korea.


D. E. Heck,
Department of Public Health, Division of Environmental Health Science, New York Medical College, Valhalla NY 10595, USA.


J. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501, Jinju-City, Gyeongsangnamdo, 660-701, Korea.


H. D. Kim,
Department of Public Health, Division of Environmental Health Science, New York Medical College, Valhalla NY 10595, USA.

Please see the link here: https://stm.bookpi.org/ETDHR-V4/article/view/6049